IGFBP4 and pulmonary fibrosis: The reduction in lung fibrosis was quantified using a hydroxyproline assay (Figure 4B) which showed that wild‐type and mutant IGFBP‐4 had similar antifibrotic effects and significantly reduced hydroxyproline content in mouse lungs.